Zhu Yi
$7.61B
as of 07/05/24
About Zhu Yi
Zhu Yi is the chairman and CEO of Biokin Pharmaceutical, a developer of drugs including anesthesia injections, cancer drugs as well as traditional Chinese medicine treatments.
The company went public in Shanghai in January 2023, raising $136 million.
Biokin's Redmond, Washington-based subsidiary Systlmmune is a cancer drug developer.
Zhu taught immunology and microbiology at West China Medical University before striking out on his own.
Personal stats
Citizenship
People's Republic of ChinaSource of wealth
PharmaceuticalsResidence
Chengdu, People's Republic of ChinaBirth date
12/01/63 (age 60)Self-made
self-madeZhu Yi’s fortune is worth
127K
troy ounces of gold
117K
median U.S. household
76K
median U.S. income
0.152%
U.S. credit card volume
0.03%
GDP of the United States
0.022%
United States debt
Net worth history
Annual ranking
Did you know?
Zhu has a master's in biology from Fudan University and a doctorate in management from Sichuan University.
Net worth over time
Real-time ranking
Financial assets
SHANGHAI | 688506-CN
Sichuan Biokin PharmaceuticalImages © Forbes.com. All rights reserved.